A JAMA Study Just Tripled the Repeat-Overdose Risk Estimate. The First 30 Days After ED Discharge Are the Inflection Point.
Among 28,500 opioid-overdose survivors, 9% died and 21% had a repeat overdose within one year — roughly triple the prior literature estimate.
A JAMA Study Just Tripled the Repeat-Overdose Risk Estimate. The First 30 Days After ED Discharge Are the Inflection Point.
A new JAMA-published study of nearly 28,500 emergency-department-treated opioid-overdose survivors in Ontario between 2017 and 2023 found that 9% died and 21% experienced a repeat overdose within one year of discharge. The highest-risk window was the first 30 days, during which 2% of survivors died and 6% had a repeat overdose. The mortality rates are roughly three times higher than what earlier literature suggested — most of which was collected before fentanyl saturated the unregulated drug supply.
The clinical implication is direct: the moment an opioid-overdose survivor leaves the emergency department is the single highest-leverage handoff point in the entire SUD care pathway. The intervention bundle the study’s authors call for — guaranteed take-home naloxone, active warm handoff to medications for opioid use disorder (MOUD), and same-week peer follow-up — costs less per saved life than almost any other addiction intervention in the literature.
Why this matters for people in recovery
If you or someone you love is leaving an ED after an overdose: ask for a naloxone kit at discharge (most U.S. hospitals can provide one); ask whether the hospital can initiate buprenorphine on-site (most can, and the 24-hour window after an overdose is when this works best); and connect with a peer recovery coach or community navigation service before you leave the parking lot. The first 30 days are not the moment to wait for an appointment four weeks from Tuesday.
If you are in Arizona and looking for an ED-to-treatment connection that doesn’t fall through the cracks, Rize can help.
988 Suicide & Crisis Lifeline: Call or text 988. SAMHSA National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7.
Sources Cited
- 01.B
- 02.B
- 03.B
Filed Under
sciencebiologytreatment
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.